5JUL

WHO lists first Bundibugyo Ebola test

2 min read

10:12UTC

WHO added the first molecular test for Bundibugyo virus to its Emergency Use Listing on 2 July, as testing across the affected provinces climbed past 2,000 samples a day.

← Back to Ebola's toolkit arrives, outbreak climbs Jump to analysis ↓

ScienceDeveloping

Key takeaway

WHO listed the first Bundibugyo-specific diagnostic on 2 July as regional testing passed 2,000 samples a day.

WHO added the first molecular diagnostic for Bundibugyo virus (BDBV) to its Emergency Use Listing (EUL) on Thursday 2 July, the regulatory route that lets an unlicensed product be used in a crisis once WHO has vetted its quality and performance ¹. No BDBV-specific test had ever been listed before. The test reads the virus's genetic material from a blood sample, and its listing matters because every unconfirmed suspected case is a person WHO might be infectious and untraced.

Testing capacity across the affected provinces has risen from roughly 200 to 400 tests a day at two facilities to more than 2,000 a day across a network of ten laboratories. "Timely access to quality-assured diagnostic tests can make a critical difference in containing transmission," said Dr Yukiko Nakatani, a WHO assistant director-general. The manufacturer was not named in the release.

WHO had to clear a testing backlog in June and recalibrate to confirmed-only reporting , so faster confirmation now closes a gap that had repeatedly made the outbreak's own headline count lurch rather than climb cleanly. The WHO R&D Blueprint, the programme that names priority pathogens, had flagged the missing Bundibugyo diagnostic as a gap in March, three months before the outbreak surfaced; that gap is now partly closed.

Deep Analysis

In plain English

A molecular diagnostic test looks for the virus's genetic material directly in a blood sample, which is faster and more specific than tests that look for antibodies the body makes later. Until 2 July, DRC labs testing for Bundibugyo ebolavirus relied on general-purpose Ebola tests not built for this specific strain, or had to send samples to a handful of central labs, causing delays. WHO's Emergency Use Listing is a fast-track approval process for tools urgently needed during an outbreak, used when there isn't time to wait for the years-long standard review. It let ten labs start using the new test immediately, pushing daily testing capacity from under 400 to over 2,000.

Deep Analysis

Root Causes

Point-of-care diagnostics for rare pathogens like Bundibugyo ebolavirus sit in what diagnostics developers call the valley of death: a manufacturer can recoup clinical-validation and EUL-submission costs only if a large, predictable market follows, and an outbreak-limited disease offers no such market once the emergency ends.

PATH and similar non-profit intermediaries typically bridge that gap by pre-negotiating volume guarantees, which is why WHO's Emergency Use Listing route exists at all: full prequalification review, built for commercial-scale products, cannot move fast enough for an active outbreak.

A test built specifically for Bundibugyo virus would also have flagged the French returnee case faster than the general Ebola serology assay used to confirm it in late June, since a species-specific PCR target returns a positive result before antibodies appear.

Source Landscape

This story draws on neutral-leaning sources from Switzerland

Switzerland

Primary parallel: The US Centers for Disease Control and Prevention secured emergency-use authorisation for its H1N1 real-time PCR test within four weeks of the 2009 pandemic being declared, showing how an emergency pathway can compress a multi-year validation process into weeks when political will and funding align.

Counter-parallel: During the 2022 mpox emergency, non-variola orthopoxvirus PCR testing stayed confined to a handful of reference laboratories for several months, since biosafety-level requirements for handling the specimens blocked the decentralised rollout that BDBV testing achieved in ten DRC sites within weeks.

Consensus view: FIND, the Foundation for Innovative New Diagnostics, rates the Emergency Use Listing as the mechanism that let ten DRC laboratories move from screening a few hundred samples a day to over 2,000, since EUL status let local labs import the assay without waiting for full WHO prequalification, a process that typically takes years.

Counter-view: The Africa Society for Laboratory Medicine counters that listing alone does not solve the cartridge cost and cold-chain gap; each of the ten labs still needs continuous 2-8°C storage and a steady cartridge supply that a DRC health budget cannot sustain once outbreak-response funding tapers off.

Key tension: Whether the ten-laboratory network built for this outbreak survives as permanent testing capacity or reverts to two facilities once the emergency listing's associated funding ends.

Sources:WHO

Mentions:Bundibugyo ebolavirus →WHO R&D Blueprint →DR Congo →Emergency Use Listing →World Health Organization →

First Reported In

Update #9 · Ebola's toolkit arrives, outbreak climbs

WHO· 5 Jul 2026

Read original →

Different Perspectives

Germany (evacuation recipient)

Germany received the Bundibugyo outbreak's third international medical evacuation on 13 July, a US humanitarian worker infected in Bunia on 10 July. The evacuation, following a French doctor's 24 June departure and May's first US case, tests whether isolation and biocontainment protocols scale beyond DR Congo's own borders.

Pennsylvania Department of Public Health

PDPH retested and retracted a false-positive measles wastewater signal on 6 July, then confirmed and publicised a real airport exposure from 4 July, with commissioner Palak Raval-Nelson stressing there is no broad threat to the general public. The national count, 2,231 cases across 42 states by 9 July, is on pace to beat 2025's 2,289-case record before September.

World Health Organization

WHO published its first dedicated Blueprint on fungal disease and antifungal resistance on 1 July, estimating more than 300 million people suffer serious fungal disease annually. The Blueprint names the gap in WHO's own AMR strategy rather than waiting for an external audit to force the admission.

Africa CDC

Africa CDC issued a formal 11 July appeal for responder protection, training and psychosocial support after health-worker infections tripled from 34 to 112 in a month. The appeal repeats June's unmet call for a rapid Bundibugyo diagnostic test, showing the ask has shifted from tools to basic safety and pay.

Front-line health workers, Ituri Province

Health workers in Ituri Province walked off the job or threatened to strike over unpaid hazard pay and delayed salaries, even as responder infections tripled to 112 with 35 dead. Their absence narrows the isolation workforce the CDC's model says must reach 70% coverage to avoid a 20,000-case worst case.

ECDC

ECDC co-published the isolation and contact-tracing figures behind WHO's DON612, tracking Ituri's isolation rate rising from 35 to 44 percent while still rating EU/EEA import risk as very low. Brussels backs the WHO line against travel restrictions, the position France's own contact-tracing response, not the US entry ban, actually validated.